Assess the efficacy, safety, and potential indications for new and emerging PrEP options скачать в хорошем качестве

Assess the efficacy, safety, and potential indications for new and emerging PrEP options

The long-awaited approval of a second long-acting injectable PrEP formulation — twice-yearly lenacapavir — has come. What are the most important things clinicians need to understand when considering prescribing this new agent? How does Q6 months LA lenacapavir differ from already available LA cabotegravir? Which patients is appropriate for? What kinds of monitoring are required, both at treatment initiation and with every following injection? What are the predominant safety issues, and how should they be managed? Join us as Matthew Spinelli, MD, MAS, Associate Professor of HIV, Infectious Disease, and Global Medicine at Zuckerberg San Francisco General Hospital, shares his experience and expertise in helping clinicians considering either of these LA PrEP options in this issue of eHIV Review. #HIV #PrEP #Clinicians